Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 462

1.

White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.

Wiebenga OT, Schoonheim MM, Hulst HE, Nagtegaal GJ, Strijbis EM, Steenwijk MD, Polman CH, Pouwels PJ, Barkhof F, Geurts JJ.

AJNR Am J Neuroradiol. 2016 Jun;37(6):1030-7. doi: 10.3174/ajnr.A4690. Epub 2016 Mar 10.

2.

Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice.

Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BM, Lehr L, Stubinski B, Kappos L.

Mult Scler Relat Disord. 2014 Mar;3(2):147-55. doi: 10.1016/j.msard.2013.07.001. Epub 2013 Jul 31. Review.

3.

Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis.

Wiebenga OT, Klauser AM, Schoonheim MM, Nagtegaal GJ, Steenwijk MD, van Rossum JA, Polman CH, Barkhof F, Pouwels PJ, Geurts JJ.

AJNR Am J Neuroradiol. 2015 Jun;36(6):1116-23. doi: 10.3174/ajnr.A4252. Epub 2015 Mar 5.

4.

Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.

Vennegoor A, van Rossum JA, Polman CH, Wattjes MP, Killestein J.

Mult Scler. 2015 Oct;21(12):1600-3. doi: 10.1177/1352458514567728. Epub 2015 Feb 6.

PMID:
25662344
5.

Functional brain networks: linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG study.

Tewarie P, Schoonheim MM, Schouten DI, Polman CH, Balk LJ, Uitdehaag BM, Geurts JJ, Hillebrand A, Barkhof F, Stam CJ.

Hum Brain Mapp. 2015 Feb;36(2):603-18. doi: 10.1002/hbm.22650. Epub 2014 Oct 8.

PMID:
25293505
6.

Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Sandbrink R, Ascherio A, Pohl C.

Ann Clin Transl Neurol. 2014 Aug;1(8):605-17. doi: 10.1002/acn3.91. Epub 2014 Aug 22.

7.

Toward the use of proxy reports for estimating long-term patient-reported outcomes in multiple sclerosis.

Sonder JM, Balk LJ, van der Linden FA, Bosma LV, Polman CH, Uitdehaag BM.

Mult Scler. 2015 Dec;21(14):1865-71. doi: 10.1177/1352458514544078. Epub 2014 Sep 25.

PMID:
25257617
8.

Multiple sclerosis: current knowledge and future outlook.

Kamm CP, Uitdehaag BM, Polman CH.

Eur Neurol. 2014;72(3-4):132-41. doi: 10.1159/000360528. Epub 2014 Jul 30. Review.

9.

Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.

Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag BM, Polman CH, Killestein J.

Mult Scler. 2015 Apr;21(4):481-4. doi: 10.1177/1352458514541507. Epub 2014 Jul 30.

PMID:
25078275
10.

Disruption of structural and functional networks in long-standing multiple sclerosis.

Tewarie P, Steenwijk MD, Tijms BM, Daams M, Balk LJ, Stam CJ, Uitdehaag BM, Polman CH, Geurts JJ, Barkhof F, Pouwels PJ, Vrenken H, Hillebrand A.

Hum Brain Mapp. 2014 Dec;35(12):5946-61. doi: 10.1002/hbm.22596. Epub 2014 Jul 22.

PMID:
25053254
11.

Detecting clinically-relevant changes in progressive multiple sclerosis.

Bosma LV, Sonder JM, Kragt JJ, Polman CH, Uitdehaag BM.

Mult Scler. 2015 Feb;21(2):171-9. doi: 10.1177/1352458514540969. Epub 2014 Jul 10.

PMID:
25013153
12.

Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.

Balk LJ, Steenwijk MD, Tewarie P, Daams M, Killestein J, Wattjes MP, Vrenken H, Barkhof F, Polman CH, Uitdehaag BM, Petzold A.

J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):419-24. doi: 10.1136/jnnp-2014-308189. Epub 2014 Jun 27.

PMID:
24973342
13.

A computer-based screening method for distress in patients with multiple sclerosis: a feasibility study.

Boeschoten RE, Uitdehaag BM, van Oppen P, de Groot V, Collette EH, Bakker KA, Polman CH, Dekker J.

JMIR Res Protoc. 2014 Jun 4;3(2):e29. doi: 10.2196/resprot.3098.

14.

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH.

Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.

15.

Morphological features of MS lesions on FLAIR* at 7 T and their relation to patient characteristics.

Kilsdonk ID, Lopez-Soriano A, Kuijer JP, de Graaf WL, Castelijns JA, Polman CH, Luijten PR, Geurts JJ, Barkhof F, Wattjes MP.

J Neurol. 2014 Jul;261(7):1356-64. doi: 10.1007/s00415-014-7351-6. Epub 2014 Apr 29.

PMID:
24777693
16.

Structural degree predicts functional network connectivity: a multimodal resting-state fMRI and MEG study.

Tewarie P, Hillebrand A, van Dellen E, Schoonheim MM, Barkhof F, Polman CH, Beaulieu C, Gong G, van Dijk BW, Stam CJ.

Neuroimage. 2014 Aug 15;97:296-307. doi: 10.1016/j.neuroimage.2014.04.038. Epub 2014 Apr 23.

PMID:
24769185
17.

Do patient and proxy agree? Long-term changes in multiple sclerosis physical impact and walking ability on patient-reported outcome scales.

Sonder JM, Balk LJ, Bosma LV, Polman CH, Uitdehaag BM.

Mult Scler. 2014 Oct;20(12):1616-23. doi: 10.1177/1352458514529173. Epub 2014 Apr 7.

PMID:
24710798
18.

Client-centred therapy in multiple sclerosis: more intensive diagnostic evaluation and less intensive treatment.

Eyssen IC, Dekker J, de Groot V, Steultjens EM, Knol DL, Polman CH, Steultjens MP.

J Rehabil Med. 2014 Jun;46(6):527-31. doi: 10.2340/16501977-1797.

19.

A dam for retrograde axonal degeneration in multiple sclerosis?

Balk LJ, Twisk JW, Steenwijk MD, Daams M, Tewarie P, Killestein J, Uitdehaag BM, Polman CH, Petzold A.

J Neurol Neurosurg Psychiatry. 2014 Jul;85(7):782-9. doi: 10.1136/jnnp-2013-306902. Epub 2014 Jan 28.

PMID:
24474822
20.

Vitamin D as an early predictor of multiple sclerosis activity and progression.

Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalbán X, Edan G, Barkhof F, Pleimes D, Radü EW, Sandbrink R, Kappos L, Pohl C.

JAMA Neurol. 2014 Mar;71(3):306-14. doi: 10.1001/jamaneurol.2013.5993.

21.

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study.

Freedman MS, De Stefano N, Barkhof F, Polman CH, Comi G, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Lehr L, Stubinski B, Jack DL, Kappos L.

J Neurol. 2014 Mar;261(3):490-9. doi: 10.1007/s00415-013-7222-6. Epub 2014 Jan 12.

22.

Disease course heterogeneity and OCT in multiple sclerosis.

Balk LJ, Tewarie P, Killestein J, Polman CH, Uitdehaag B, Petzold A.

Mult Scler. 2014 Aug;20(9):1198-206. doi: 10.1177/1352458513518626. Epub 2014 Jan 8.

PMID:
24402036
23.

Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis.

Schoonheim MM, Geurts J, Wiebenga OT, De Munck JC, Polman CH, Stam CJ, Barkhof F, Wink AM.

Mult Scler. 2014 Jul;20(8):1058-65. doi: 10.1177/1352458513516892. Epub 2013 Dec 17.

PMID:
24347184
24.

Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla.

Kilsdonk ID, Wattjes MP, Lopez-Soriano A, Kuijer JP, de Jong MC, de Graaf WL, Conijn MM, Polman CH, Luijten PR, Geurts JJ, Geerlings MI, Barkhof F.

Eur Radiol. 2014 Apr;24(4):841-9. doi: 10.1007/s00330-013-3080-y. Epub 2013 Dec 9.

PMID:
24317461
25.

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.

De Stefano N, Comi G, Kappos L, Freedman MS, Polman CH, Uitdehaag BM, Hennessy B, Casset-Semanaz F, Lehr L, Stubinski B, Jack DL, Barkhof F.

J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):647-53. doi: 10.1136/jnnp-2013-306289. Epub 2013 Nov 29.

26.

Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI?

Hulst HE, Gehring K, Uitdehaag BM, Visser LH, Polman CH, Barkhof F, Sitskoorn MM, Geurts JJ.

Mult Scler. 2014 Jul;20(8):1131-4. doi: 10.1177/1352458513513969. Epub 2013 Nov 25.

PMID:
24277326
27.

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

Edan G, Kappos L, Montalbán X, Polman CH, Freedman MS, Hartung HP, Miller D, Barkhof F, Herrmann J, Lanius V, Stemper B, Pohl C, Sandbrink R, Pleimes D; BENEFIT Study Group.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1183-9. doi: 10.1136/jnnp-2013-306222. Epub 2013 Nov 11.

28.

Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study.

Van der Meer ML, Tewarie P, Schoonheim MM, Douw L, Barkhof F, Polman CH, Stam CJ, Hillebrand A.

Neuroimage Clin. 2013 May 13;2:727-34. doi: 10.1016/j.nicl.2013.05.003. eCollection 2013.

29.

Functional brain network analysis using minimum spanning trees in Multiple Sclerosis: an MEG source-space study.

Tewarie P, Hillebrand A, Schoonheim MM, van Dijk BW, Geurts JJ, Barkhof F, Polman CH, Stam CJ.

Neuroimage. 2014 Mar;88:308-18. doi: 10.1016/j.neuroimage.2013.10.022. Epub 2013 Oct 22.

PMID:
24161625
30.

Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis.

Sonder JM, Burggraaff J, Knol DL, Polman CH, Uitdehaag BM.

Mult Scler. 2014 Apr;20(4):481-8. doi: 10.1177/1352458513501570. Epub 2013 Sep 9.

PMID:
24019305
31.

Analyzing differences between patient and proxy on Patient Reported Outcomes in multiple sclerosis.

Sonder JM, Holman R, Knol DL, Bosma LV, Polman CH, Uitdehaag BM.

J Neurol Sci. 2013 Nov 15;334(1-2):143-7. doi: 10.1016/j.jns.2013.08.014. Epub 2013 Aug 15.

PMID:
24018128
32.

Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

Hegen H, Millonig A, Bertolotto A, Comabella M, Giovanonni G, Guger M, Hoelzl M, Khalil M, Killestein J, Lindberg R, Malucchi S, Mehling M, Montalban X, Polman CH, Rudzki D, Schautzer F, Sellebjerg F, Sørensen PS, Deisenhammer F.

Mult Scler. 2014 Apr;20(5):577-87. doi: 10.1177/1352458513503597. Epub 2013 Sep 5.

PMID:
24009164
33.

Sex-specific extent and severity of white matter damage in multiple sclerosis: implications for cognitive decline.

Schoonheim MM, Vigeveno RM, Rueda Lopes FC, Pouwels PJ, Polman CH, Barkhof F, Geurts JJ.

Hum Brain Mapp. 2014 May;35(5):2348-58. doi: 10.1002/hbm.22332. Epub 2013 Aug 24.

PMID:
23982918
34.

Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis.

van de Kraats C, Killestein J, Popescu V, Rijkers E, Vrenken H, Lütjohann D, Barkhof F, Polman CH, Teunissen CE.

Mult Scler. 2014 Apr;20(4):412-7. doi: 10.1177/1352458513499421. Epub 2013 Aug 19.

PMID:
23959711
35.

Cognitive and clinical dysfunction, altered MEG resting-state networks and thalamic atrophy in multiple sclerosis.

Tewarie P, Schoonheim MM, Stam CJ, van der Meer ML, van Dijk BW, Barkhof F, Polman CH, Hillebrand A.

PLoS One. 2013 Jul 31;8(7):e69318. doi: 10.1371/journal.pone.0069318. Print 2013.

36.

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.

Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, Hartung HP, Miller D, Montalban X, Kappos L, Edan G, Pleimes D, Beckman K, Stemper B, Polman CH, Sandbrink R, Barkhof F.

Mult Scler. 2014 Feb;20(2):234-42. doi: 10.1177/1352458513494491. Epub 2013 Jul 10.

PMID:
23842212
37.

Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.

van Rossum JA, Vennegoor A, Balk L, Uitdehaag BM, Polman CH, Killestein J.

Mult Scler. 2014 Jan;20(1):108-11. doi: 10.1177/1352458513495582. Epub 2013 Jul 4.

PMID:
23828867
38.

Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration.

Kearney H, Rocca MA, Valsasina P, Balk L, Sastre-Garriga J, Reinhardt J, Ruggieri S, Rovira A, Stippich C, Kappos L, Sprenger T, Tortorella P, Rovaris M, Gasperini C, Montalban X, Geurts JJ, Polman CH, Barkhof F, Filippi M, Altmann DR, Ciccarelli O, Miller DH, Chard DT.

Mult Scler. 2014 Jan;20(1):72-80. doi: 10.1177/1352458513492245. Epub 2013 Jun 27.

39.

Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients.

Lukas C, Sombekke MH, Bellenberg B, Hahn HK, Popescu V, Bendfeldt K, Radue EW, Gass A, Borgwardt SJ, Kappos L, Naegelin Y, Knol DL, Polman CH, Geurts JJ, Barkhof F, Vrenken H.

Radiology. 2013 Nov;269(2):542-52. doi: 10.1148/radiol.13122566. Epub 2013 Jun 4.

PMID:
23737540
40.

PML in a patient treated with dimethyl fumarate from a compounding pharmacy.

van Oosten BW, Killestein J, Barkhof F, Polman CH, Wattjes MP.

N Engl J Med. 2013 Apr 25;368(17):1658-9. doi: 10.1056/NEJMc1215357. No abstract available. Erratum in: N Engl J Med. 2013 May 16;368(20):1950.

41.

Brain atrophy and lesion load predict long term disability in multiple sclerosis.

Popescu V, Agosta F, Hulst HE, Sluimer IC, Knol DL, Sormani MP, Enzinger C, Ropele S, Alonso J, Sastre-Garriga J, Rovira A, Montalban X, Bodini B, Ciccarelli O, Khaleeli Z, Chard DT, Matthews L, Palace J, Giorgio A, De Stefano N, Eisele P, Gass A, Polman CH, Uitdehaag BM, Messina MJ, Comi G, Filippi M, Barkhof F, Vrenken H; MAGNIMS Study Group.

J Neurol Neurosurg Psychiatry. 2013 Oct;84(10):1082-91. doi: 10.1136/jnnp-2012-304094. Epub 2013 Mar 23.

PMID:
23524331
42.

Cognitive impairment in MS: impact of white matter integrity, gray matter volume, and lesions.

Hulst HE, Steenwijk MD, Versteeg A, Pouwels PJ, Vrenken H, Uitdehaag BM, Polman CH, Geurts JJ, Barkhof F.

Neurology. 2013 Mar 12;80(11):1025-32. doi: 10.1212/WNL.0b013e31828726cc. Epub 2013 Mar 6.

PMID:
23468546
43.

A cluster randomised controlled trial on the efficacy of client-centred occupational therapy in multiple sclerosis: good process, poor outcome.

Eyssen IC, Steultjens MP, de Groot V, Steultjens EM, Knol DL, Polman CH, Dekker J.

Disabil Rehabil. 2013 Sep;35(19):1636-46. doi: 10.3109/09638288.2012.748845. Epub 2013 Jan 24.

PMID:
23343363
44.

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.

Kappos L, O'Connor PW, Polman CH, Vermersch P, Wiendl H, Pace A, Zhang A, Hotermans C.

J Neurol. 2013 May;260(5):1388-95. doi: 10.1007/s00415-012-6809-7. Epub 2013 Jan 5.

45.

Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis.

Sombekke MH, Wattjes MP, Balk LJ, Nielsen JM, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F.

Neurology. 2013 Jan 1;80(1):69-75. doi: 10.1212/WNL.0b013e31827b1a67. Epub 2012 Dec 12.

PMID:
23243070
46.

The first 10 years with multiple sclerosis: the longitudinal course of daily functioning.

Beckerman H, Kempen JC, Knol DL, Polman CH, Lankhorst GJ, de Groot V.

J Rehabil Med. 2013 Jan;45(1):68-75. doi: 10.2340/16501977-1079.

47.

Microcystic macular oedema confirmed, but not specific for multiple sclerosis.

Balk LJ, Killestein J, Polman CH, Uitdehaag BM, Petzold A.

Brain. 2012 Dec;135(Pt 12):e226; author reply e227. doi: 10.1093/brain/aws216. Epub 2012 Oct 17. No abstract available.

PMID:
23078994
48.

Multicontrast MR imaging at 7T in multiple sclerosis: highest lesion detection in cortical gray matter with 3D-FLAIR.

Kilsdonk ID, de Graaf WL, Soriano AL, Zwanenburg JJ, Visser F, Kuijer JP, Geurts JJ, Pouwels PJ, Polman CH, Castelijns JA, Luijten PR, Barkhof F, Wattjes MP.

AJNR Am J Neuroradiol. 2013 Apr;34(4):791-6. doi: 10.3174/ajnr.A3289. Epub 2012 Oct 4.

49.

Subcortical atrophy and cognition: sex effects in multiple sclerosis.

Schoonheim MM, Popescu V, Rueda Lopes FC, Wiebenga OT, Vrenken H, Douw L, Polman CH, Geurts JJ, Barkhof F.

Neurology. 2012 Oct 23;79(17):1754-61. doi: 10.1212/WNL.0b013e3182703f46. Epub 2012 Sep 26.

PMID:
23019265
50.

Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.

Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J.

Mult Scler. 2013 Apr;19(5):593-600. doi: 10.1177/1352458512460604. Epub 2012 Sep 19.

PMID:
22992450

Supplemental Content

Loading ...
Support Center